Market Research Logo

Prader-Willi Syndrome (PWS) - Pipeline Review, H2 2015

Prader-Willi Syndrome (PWS) - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Prader-Willi Syndrome (PWS) - Pipeline Review, H2 2015’, provides an overview of the Prader-Willi Syndrome (PWS)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Prader-Willi Syndrome (PWS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Prader-Willi Syndrome (PWS) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Prader-Willi Syndrome (PWS)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Prader-Willi Syndrome (PWS) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Prader-Willi Syndrome (PWS) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Prader-Willi Syndrome (PWS) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Prader-Willi Syndrome (PWS)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Prader-Willi Syndrome (PWS) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Prader-Willi Syndrome (PWS) Overview
Therapeutics Development
Pipeline Products for Prader-Willi Syndrome (PWS) - Overview
Pipeline Products for Prader-Willi Syndrome (PWS) - Comparative Analysis
Prader-Willi Syndrome (PWS) - Therapeutics under Development by Companies
Prader-Willi Syndrome (PWS) - Therapeutics under Investigation by Universities/Institutes
Prader-Willi Syndrome (PWS) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Prader-Willi Syndrome (PWS) - Products under Development by Companies
Prader-Willi Syndrome (PWS) - Products under Investigation by Universities/Institutes
Prader-Willi Syndrome (PWS) - Companies Involved in Therapeutics Development
Alize Pharma SAS
Chong Kun Dang Pharmaceutical Corp.
Essentialis, Inc.
Ferring International Center S.A.
LG Life Sciences, Ltd.
P2D Bioscience
Rhythm Pharmaceuticals
Prader-Willi Syndrome (PWS) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AZP-531 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
beloranib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
betahistine hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
carbetocin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
diazoxide choline CR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
K-671 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OV-401 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
setmelanotide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Activate snRNP-N for Prader-Willi Syndrome - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Antagonize Ghrelin Receptor for Prader-Willi Syndrome - Drug Profile
Product Description
Mechanism of Action
R&D Progress
somatropin (recombinant) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Prader-Willi Syndrome (PWS) - Recent Pipeline Updates
Prader-Willi Syndrome (PWS) - Dormant Projects
Prader-Willi Syndrome (PWS) - Product Development Milestones
Featured News & Press Releases
Jun 04, 2015: Rhythm Initiates Two Phase 2 Clinical Trials of Setmelanotide in Rare Genetic Disorders of Obesity Caused by MC4 Pathway Deficiencies
May 28, 2015: Zafgen Completes Enrollment of U.S. Phase 3 Trial of Beloranib in Prader-Willi Syndrome
May 08, 2015: Zafgen Presents Positive Safety And Efficacy Data From Phase 2 Trial Of Beloranib In Severe Obesity And Proof Of Concept Trial In Prader-Willi Syndrome At ECO 2015
Mar 26, 2015: Essentialis Presents Results From the First Phase of Clinical Study PC025 Evaluating DCCR in the Treatment of Prader-Willi Syndrome at ACMG Annual Clinical Genetic Meeting
Mar 02, 2015: Alize Pharma launches Phase II clinical trial of AZP-531 in Prader-Willi syndrome
Nov 14, 2014: Essentialis To Present Clinical Update At The Annual Research Conference Of The Foundation For Prader-Willi Research
Oct 01, 2014: Zafgen Announces Initiation of Phase 3 Trial of Beloranib in Prader-Willi Syndrome
Jul 23, 2014: Essentialis Secures Foundation for Prader-Willi Research Grant to Help Advance DCCR in the Treatment of Prader-Willi Syndrome
Jul 10, 2014: Zafgen Granted Orphan Drug Designation in the European Union for Beloranib, a First-in-Class MetAP2 Inhibitor for the Treatment of Prader-Willi Syndrome
Jun 27, 2014: Essentialis Announces the Dosing of the First Patient in a Clinical Study of DCCR in Prader-Willi Syndrome
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Prader-Willi Syndrome (PWS), H2 2015
Number of Products under Development for Prader-Willi Syndrome (PWS) - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Investigation by Universities/Institutes, H2 2015
Prader-Willi Syndrome (PWS) - Pipeline by Alize Pharma SAS, H2 2015
Prader-Willi Syndrome (PWS) - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2015
Prader-Willi Syndrome (PWS) - Pipeline by Essentialis, Inc., H2 2015
Prader-Willi Syndrome (PWS) - Pipeline by Ferring International Center S.A., H2 2015
Prader-Willi Syndrome (PWS) - Pipeline by LG Life Sciences, Ltd., H2 2015
Prader-Willi Syndrome (PWS) - Pipeline by P2D Bioscience, H2 2015
Prader-Willi Syndrome (PWS) - Pipeline by Rhythm Pharmaceuticals, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Prader-Willi Syndrome (PWS) Therapeutics - Recent Pipeline Updates, H2 2015
Prader-Willi Syndrome (PWS) - Dormant Projects, H2 2015
List of Figures
Number of Products under Development for Prader-Willi Syndrome (PWS), H2 2015
Number of Products under Development for Prader-Willi Syndrome (PWS) - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report